October 11, 2017
Impressions from the 9 th Cannabinoid Conference 2017 organized by the International Association for Cannabinoid Medicines (IACM) from September 29-30, 2017 in Cologne, Germany.
by Bernd Keller, Ph.D.
Senior Research Scientist, Salvation Bioscience
The IACM Cannabinoid Conference is held every 2 years and started in 2001 (www.cannabis-med.org). Topics of the talks covered were mostly clinical and medical applications and patient therapies employing cannabinoids & related substances and respective legal issues in different countries around the world.
The significance of this conference is demonstrated by almost 400 attendees coming from more than 30! different countries, including 18 participants from Canada alone (http://cannabinoidconference2017.org/tnlist)
One of the greatest frustrations observed is the many legal issues and other (e.g. financial) barriers that physicians face when trying to implement and prescribe cannabinoid medicines and therapies in their daily routine work. There is hope that novel legislation and ever improving acceptance will eventually overcome these obstacles, but this will take time and great efforts.
Another major issue reported (-that is more relevant to our business) is the often-found inaccessibility of cannabinoid medicines in sufficient quality, potency or quantity.
Physicians and clinical personnel need access to